EAU 2026 Prostate Cancer

Viewing 1-20 of 49 articles

EAU 2026: A Phase II, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer

EAU 2026: Discussant: Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer

EAU 2026: PRIMARY2 – Impact of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Non-Suspicious Findings on mpMRI: A Multi-Center, Phase III, Randomized Trial

EAU 2026: Discussant - PRIMARY2 – Impact of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Non-Suspicious Findings on mpMR

EAU 2026: What Do You Need for Decision-making in mHSPC in 2026?

EAU 2026: Macroscopic Local Relapse after RP in the Context of High-risk nmHSPC

EAU 2026: Presentation of APCCC 2024/2025 Results on Synchronous High-volume mHSPC & Voting

EAU 2026: Presentation of APCCC 2024/2025 Results on High-risk nmHSPC & Voting

EAU 2026: Update on High-risk Non-metastatic Hormone-sensitive Prostate Cancer

EAU 2026: News in the mHSPC Setting, PARP Inhibitors, and More

EAU 2026: Validation of the EAU Favorable and Unfavorable Intermediate-Risk Prognostic Groups for Predicting Biochemical Recurrence After Radical Prostatectomy in Contemporary Prostate Cancer Patients: The Added Value of MRI-Features

EAU 2026: DISSECTION 2.0 – Extended Pelvic Lymph Node Dissection versus No Pelvic Lymph Node Dissection at Radical Prostatectomy in PSMA PET Negative Staged Men: A Multicenter, Randomized Phase III Trial

EAU 2026: Co-PSMA Trial: Prospective Comparison of 64Cu-SAR-Bis-PSMA Versus 68Ga PSMA-11 PET CT for Prostate Cancer Detection in Patients with Biochemical Recurrence After Radical Prostatectomy

EAU 2026: PRESIDENT: PRostatEctomy Surgery in Disseminated Low-Volume Metastatic Hormone Sensitive Prostate Cancer with Endpoint Assessment Using Nuclear Imaging Technology Using PSMA PET/CT Imaging: A Definitive Randomized Controlled Trial

EAU 2026: TRAIN: A Phase III Randomized Controlled Clinical Trial of Radiotherapy with Radiosensitization Versus Intravesical BCG Therapy for High Risk NMIBC

EAU 2026: State of the Art Lecture: Why Are Germline and Somatic Alterations in Prostate Cancer Important?

EAU 2026: State of the Art Lecture: PARP Inhibitors in mHSPC and mCRPC

EAU 2026: How to Optimize Germline and Somatic Testing in Prostate Cancer?

EAU 2026: When to Use ctDNA in Prostate Cancer?

EAU 2026: How to Optimize Tissue Biopsy Acquisition? Why, Who, When, Where, and How

1
2
3